Weight loss and diabetes drugs target regulatory pathways involved in metabolism that the microbes in your gut and certain molecules from food already play a key role in regulating.
Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly s Mounjaro than those taking Novo Nordisk s popular rival weight loss drug.
Novo Nordisk has announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France.
Novo Nordisk will launch its hugely popular anti-obesity drug in Japan on February 22, its first launch in Asia, even as it struggles to keep up with demand in existing markets.